Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Research and Development | December 16, 2024 | December 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 16, 2024 · Filed December 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,829 |
Reported balance
After 2024-12-16 transaction · row 1
1 source rowRow 1 · 2024-12-16 · Tax withholding · Disposed 304 · Balance 48,829 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,849 |
Reported balance
Holding disclosure · report date 2024-12-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,849 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse as Trustee | 4,605 |
Reported balance
Holding disclosure · report date 2024-12-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,605 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 08, 2019 Filed Nov 12, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $335.45 | $134,180.00 |
DisclosureSEC source: 0001708138-19-000010 · edgardoc.xml · nonDerivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,019 F3 · price: Represents volume-weighted average price of sales of 400 shares of Company stock on November 8, 2019 at prices ranging from $335.02 to $335.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2019 at each separate price. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $334.66 | $33,466.00 |
DisclosureSEC source: 0001708138-19-000010 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,419 F2 · price: Represents volume-weighted average price of sales of 100 shares of Company stock on November 8, 2019 at prices ranging from $334.48 to $334.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2019 at each separate price. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $333.32 | $66,664.00 |
DisclosureSEC source: 0001708138-19-000010 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,519 F1 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on November 8, 2019 at prices ranging from $333.31 to $333.32. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2019 at each separate price. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $330.56 | $33,056.00 |
DisclosureSEC source: 0001708138-19-000010 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,719 Read SEC document |
| May 24, 2019 Filed Nov 12, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-19-000010 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,150 Read SEC document |
| May 14, 2019 Filed May 15, 2019 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,278 | $306.37 | $1,004,280.86 |
DisclosureSEC source: 0001237899-19-000012 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,450 F2 · price: Represents volume-weighted average price of sales of 3,278 shares of Company stock on May 14, 2019 at prices ranging from $306.00 to $306.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 14, 2019 at each separate price. Read SEC document |
| May 14, 2019 Filed May 15, 2019 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6,575 | $305.43 | $2,008,202.25 |
DisclosureSEC source: 0001237899-19-000012 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,728 F1 · price: Represents volume-weighted average price of sales of 6,575 shares of Company stock on May 14, 2019 at prices ranging from $305.05 to $305.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 14, 2019 at each separate price. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001237899-19-000012 · edgardoc.xml · derivative · entry 7 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,079 Underlying: Common Stock · 25,000 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: With respect to 75,000 underlying shares, the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 48,079 underlying shares, the stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 15,147 | $304.20 | $4,607,717.40 |
DisclosureSEC source: 0001237899-19-000012 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,303 Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 25,000 | $52.03 | $1,300,750.00 |
DisclosureSEC source: 0001237899-19-000012 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $381.40 | $0.00 |
DisclosureSEC source: 0001708138-18-000029 · edgardoc.xml · derivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-12-12 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 24, 2018 Filed May 25, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11,407 | $295.09 | $3,366,091.63 |
DisclosureSEC source: 0001708138-18-000007 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,973 F1 · kind: Represents volume-weighted average price of sales of 11,407 shares of Company stock on May 24, 2018 at prices ranging from $295.00 to $295.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 24, 2018 at each separate price. Read SEC document |
| May 23, 2018 Filed May 25, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 26,736 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-18-000007 · edgardoc.xml · derivative · entry 7 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,736 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 23, 2018 Filed May 25, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 15,329 | $293.68 | $4,501,820.72 |
DisclosureSEC source: 0001708138-18-000007 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,380 Read SEC document |
| May 23, 2018 Filed May 25, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 26,736 | $30.63 | $818,923.68 |
DisclosureSEC source: 0001708138-18-000007 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001237899-17-000027 · edgardoc.xml · derivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-12-12 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $541.70 | $54,170.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 22 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,950 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $540.04 | $54,004.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 21 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,050 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $539.36 | $107,872.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 20 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,150 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $539.00 to $539.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 600 | $538.39 | $323,034.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 19 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,350 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 600 shares of Company stock on June 22, 2017 at prices ranging from $538.00 to $538.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $537.42 | $107,484.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 18 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,950 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $537.19 to $537.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 800 | $536.46 | $429,168.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 17 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,150 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 800 shares of Company stock on June 22, 2017 at prices ranging from $536.15 to $536.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 800 | $535.37 | $428,296.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 16 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,950 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 800 shares of Company stock on June 22, 2017 at prices ranging from $535.01 to $535.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 700 | $534.64 | $374,248.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 15 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,750 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 700 shares of Company stock on June 22, 2017 at prices ranging from $534.44 to $534.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 905 | $533.49 | $482,808.45 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 14 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,450 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 905 shares of Company stock on June 22, 2017 at prices ranging from $533.08 to $533.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $532.44 | $266,220.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 13 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,355 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 500 shares of Company stock on June 22, 2017 at prices ranging from $532.05 to $532.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 900 | $531.42 | $478,278.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 12 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,855 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 900 shares of Company stock on June 22, 2017 at prices ranging from $531.05 to $531.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 800 | $530.64 | $424,512.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 11 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,755 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 800 shares of Company stock on June 22, 2017 at prices ranging from $530.38 to $530.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $529.61 | $52,961.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 10 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,555 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 600 | $526.45 | $315,870.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 9 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,655 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 600 shares of Company stock on June 22, 2017 at prices ranging from $526.00 to $526.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $525.10 | $210,040.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 8 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,255 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 400 shares of Company stock on June 22, 2017 at prices ranging from $525.00 to $525.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 101 | $524.08 | $52,932.08 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 7 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,655 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $523.52 | $104,704.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,756 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $523.50 to $523.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $522.80 | $104,560.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,956 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $522.74 to $522.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $521.70 | $52,170.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,156 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · derivative · entry 26 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,736 Underlying: Common Stock · 20,000 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 10,493 | $510.02 | $5,351,639.86 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,256 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,201 | $510.02 | $612,534.02 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,749 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 20,000 | $30.63 | $612,600.00 |
DisclosureSEC source: 0001708138-17-000010 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $474.48 | $47,448.00 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · nonDerivative · entry 15 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,950 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $472.95 | $47,295.00 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · nonDerivative · entry 14 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,050 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $471.15 | $47,115.00 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · nonDerivative · entry 13 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,150 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,426 | $470.57 | $1,141,602.82 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · nonDerivative · entry 12 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,250 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 2,426 shares of Company stock on June 15, 2017 at prices ranging from $470.03 to $470.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 15, 2017 at each separate price. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,212 | $469.53 | $1,038,600.36 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · nonDerivative · entry 11 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,676 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 2,212 shares of Company stock on June 15, 2017 at prices ranging from $469.07 to $469.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 15, 2017 at each separate price. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 900 | $468.63 | $421,767.00 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · nonDerivative · entry 10 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,888 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 900 shares of Company stock on June 15, 2017 at prices ranging from $468.00 to $468.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 15, 2017 at each separate price. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $467.82 | $140,346.00 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · nonDerivative · entry 9 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,788 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on June 15, 2017 at prices ranging from $467.70 to $467.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 15, 2017 at each separate price. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 185 | $466.52 | $86,306.20 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · nonDerivative · entry 8 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,088 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 185 shares of Company stock on June 15, 2017 at prices ranging from $466.49 to $466.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 15, 2017 at each separate price. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,244 | $465.49 | $579,069.56 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · nonDerivative · entry 7 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,273 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 1,244 shares of Company stock on June 15, 2017 at prices ranging from $465.00 to $465.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 15, 2017 at each separate price. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $464.69 | $185,876.00 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · nonDerivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,517 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 400 shares of Company stock on June 15, 2017 at prices ranging from $464.46 to $464.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 15, 2017 at each separate price. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $463.91 | $46,391.00 |
DisclosureSEC source: 0001708138-17-000005 · edgardoc.xml · nonDerivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,917 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.